Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Decreased core muscle size is associated with worse patient survival following esophagectomy for cancer.

Sheetz KH, Zhao L, Holcombe SA, Wang SC, Reddy RM, Lin J, Orringer MB, Chang AC.

Dis Esophagus. 2013 Sep-Oct;26(7):716-22. doi: 10.1111/dote.12020. Epub 2013 Jan 25.

2.

Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.

Shridhar R, Hoffe SE, Almhanna K, Weber JM, Chuong MD, Karl RC, Meredith K.

Ann Surg Oncol. 2013 Sep;20(9):3038-43. doi: 10.1245/s10434-013-2988-4. Epub 2013 Apr 28.

PMID:
23625142
3.

Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy.

Dittrick GW, Weber JM, Shridhar R, Hoffe S, Melis M, Almhanna K, Barthel J, McLoughlin J, Karl RC, Meredith KL.

Ann Surg Oncol. 2012 May;19(5):1678-84. doi: 10.1245/s10434-011-2078-4. Epub 2011 Nov 2.

PMID:
22045465
4.

Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma.

Hong D, Lunagomez S, Kim EE, Lee JH, Bresalier RS, Swisher SG, Wu TT, Morris J, Liao Z, Komaki R, Ajani JA.

Cancer. 2005 Oct 15;104(8):1620-6.

5.

Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.

Shridhar R, Freilich J, Hoffe SE, Almhanna K, Fulp WJ, Yue B, Karl RC, Meredith K.

Ann Surg Oncol. 2014 Nov;21(12):3744-50. doi: 10.1245/s10434-014-3795-2. Epub 2014 May 23.

PMID:
24854492
6.

Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.

Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac H, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA.

Ann Thorac Surg. 2004 Oct;78(4):1152-60; discussion 1152-60. Review.

PMID:
15464463
7.

Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.

Chao YK, Chan SC, Liu YH, Chen HW, Wan YL, Chang HK, Fan KH, Liu HP.

Ann Surg. 2009 Mar;249(3):392-6. doi: 10.1097/SLA.0b013e3181949e9f.

PMID:
19247024
8.

Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.

Kauppi JT, Oksala N, Salo JA, Helin H, Karhumäki L, Kemppainen J, Sihvo EI, Räsänen JV.

Acta Oncol. 2012 May;51(5):636-44. doi: 10.3109/0284186X.2011.643822. Epub 2012 Jan 2.

PMID:
22208782
9.

A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer.

Hayashi Y, Xiao L, Suzuki A, Blum MA, Sabloff B, Taketa T, Maru DM, Welsh J, Lin SH, Weston B, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Ajani JA.

Eur J Cancer. 2012 Dec;48(18):3396-404. doi: 10.1016/j.ejca.2012.06.020. Epub 2012 Jul 31.

10.

Neoadjuvant chemoradiation therapy in patients with surgically treated esophageal cancer.

Vermund H, Pories WJ, Hillard J, Wiley AL, Youngblood R.

Acta Oncol. 2001;40(5):558-65. Review.

PMID:
11669326
11.

Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.

Spigel DR, Greco FA, Meluch AA, Lane CM, Farley C, Gray JR, Clark BL, Burris HA 3rd, Hainsworth JD.

J Clin Oncol. 2010 May 1;28(13):2213-9. doi: 10.1200/JCO.2009.24.8773. Epub 2010 Mar 29.

PMID:
20351330
12.

Evolution of standardized clinical pathways: refining multidisciplinary care and process to improve outcomes of the surgical treatment of esophageal cancer.

Markar SR, Schmidt H, Kunz S, Bodnar A, Hubka M, Low DE.

J Gastrointest Surg. 2014 Jul;18(7):1238-46. doi: 10.1007/s11605-014-2520-6. Epub 2014 Apr 29.

PMID:
24777435
13.

Survival benefits of postoperative chemoradiation for lymph node-positive esophageal squamous cell carcinoma.

Hsu PK, Huang CS, Wang BY, Wu YC, Hsu WH.

Ann Thorac Surg. 2014 May;97(5):1734-41. doi: 10.1016/j.athoracsur.2013.12.041. Epub 2014 Mar 6.

PMID:
24612702
14.

Salvage Esophagectomy After Definitive Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Who Really Benefits from this High-Risk Surgery?

Watanabe M, Mine S, Nishida K, Yamada K, Shigaki H, Matsumoto A, Sano T.

Ann Surg Oncol. 2015 Dec;22(13):4438-44. doi: 10.1245/s10434-015-4556-6. Epub 2015 Apr 11.

PMID:
25862582
15.

Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.

Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J Jr, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R.

Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):427-36.

PMID:
15380576
16.

Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma.

Wang J, Myles B, Wei C, Chang JY, Hofstetter WL, Ajani JA, Swisher SG, Cox JD, Komaki R, Liao Z, Lin SH.

Dis Esophagus. 2014 Feb-Mar;27(2):168-75. doi: 10.1111/dote.12074. Epub 2013 Apr 26.

17.

Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients.

Fujiwara Y, Yoshikawa R, Kamikonya N, Nakayama T, Kitani K, Tsujie M, Yukawa M, Inoue M, Yamamura T.

Oncol Rep. 2012 Aug;28(2):446-52. doi: 10.3892/or.2012.1847. Epub 2012 Jun 1.

18.

Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.

Liao Z, Zhang Z, Jin J, Ajani JA, Swisher SG, Stevens CW, Ho L, Smythe R, Vaporciyan AA, Putnam JB Jr, Walsh GL, Roth JA, Yao JC, Allen PK, Cox JD, Komaki R.

Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1484-93.

PMID:
15590179
19.

Outcomes With Open and Minimally Invasive Ivor Lewis Esophagectomy After Neoadjuvant Therapy.

Tapias LF, Mathisen DJ, Wright CD, Wain JC, Gaissert HA, Muniappan A, Lanuti M, Donahue DM, Morse CR.

Ann Thorac Surg. 2016 Mar;101(3):1097-103. doi: 10.1016/j.athoracsur.2015.09.062. Epub 2015 Dec 1.

PMID:
26652140
20.

Primary Gross Tumor Volume is an Important Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Trimodality Therapy.

Boggs DH, Hanna A, Burrows W, Horiba N, Suntharalingam M.

J Gastrointest Cancer. 2015 Jun;46(2):131-7. doi: 10.1007/s12029-015-9699-y.

PMID:
25759174

Supplemental Content

Support Center